GBT
TXG icon

Grove Bank & Trust’s 10x Genomics TXG Stock Holding History

Grove Bank & Trust’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34
Closed -$1.4K – 709
2023
Q3 		$1.4K Buy
+34
New +$1.77K ﹤0.01% 668

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grove Bank & Trust's TXG Position: Q4 2023 in Review

Grove Bank & Trust sold out of 10x Genomics (TXG) in Q4 2023, closing a stake of 34 shares — an estimated $1.4K sold.

Grove Bank & Trust first reported a position in TXG in Q3 2023 and held it in 1 quarter. The position peaked at $1.4K in Q3 2023. 275 funds tracked by Wall St. Rank hold TXG as of Q4 2023.

  • Grove Bank & Trust reported no remaining 10x Genomics position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 34 10x Genomics shares in Q4 2023, an estimated $1.4K.
  • Grove Bank & Trust first reported a position in 10x Genomics in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's 10x Genomics position peaked at $1.4K in Q3 2023.
  • 275 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.